ERBB2 and breast cancer: <h4>Background</h4>Baseline recurrence risk increasingly guides adjuvant endocrine therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (BC).